Novo Nordisk A/S vs Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) — how do they compare? Novo Nordisk A/S trades at $38.61 (market cap $169.08B), while Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) trades at $8.59 (market cap $9.09B). The key difference: Novo Nordisk A/S is far larger — about 18.6× Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares)'s market cap, and Novo Nordisk A/S pays the higher dividend (4.72%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Full Truck Alliance Co. Ltd. American Depositary Shares (each representing 20 Class A Ordinary Shares) for 0 Days on average.
| NVO | YMM | |
|---|---|---|
Market Cap | $169.08B | $9.09B |
Volume | 9,259,152 | 10,124,674 |
Sector | Health | Technology |
52-Week High | $63.98 | $13.30 |
52-Week Low | $35.29 | $7.54 |
Typical Hold Time | 116 Days | 0 Days |
Enterprise Value | $183.28B | $5.57B |
Dividend Yield | 4.72% | 3.84% |
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.12, down 1.19% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $0.96, beating expectations by 17%, continuing a trend of earnings outperformance. Valuation metrics remain attractive with P/E of 9.67 and ROE of 59.82%, while recent news highlights pipeline expansion through $4 billion in licensing deals and progress on oral Wegovy formulations.
The stock presents a compelling value opportunity with strong profitability and growth prospects in obesity/diabetes markets, though technical weakness and competitive pressure from Eli Lilly create near-term headwinds. Analyst consensus remains bullish with $42.33 price target representing 11% upside potential from current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Full Truck Alliance Co. Ltd. operates a digital freight-matching platform in China, connecting shippers with truckers for cargo transport across varying distances and load types.
Read more on YMM →